Study shows first-of-its kind gene therapy can restore vision to people with an inherited retinal disorder
Patients who had lost their sight to an inherited retinal disease could see well enough to navigate a maze after being treated with a new gene therapy, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.
Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.
Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.
Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.
LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient’s eyes.
Treatment doesn’t restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.
More than 200 patients with LCA have participated in gene therapy trials since 2007.
However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn’t obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.
The Latest on: Gene therapy
Thalassaemia gene therapy trial shows 'encouraging' results
on April 18, 2018 at 7:38 pm
Scientists say they are "excited" by the results of a gene therapy trial for the inherited blood disorder beta-thalassaemia, which reduced the need for blood transfusions. In 22 patients, blood stem cells were extracted, treated and re-introduced to ... […]
Gene Therapy Shows Promise in Patients with a Blood Disorder
on April 18, 2018 at 6:00 pm
Researchers have used an experimental gene therapy developed by biotech company bluebird bio Inc. to reduce the number of blood transfusions needed in 22 people with beta-thalassemia, an inherited blood disorder. The results are another sign of the promise ... […]
Gene replacement therapy shows promise in patients with blood disorder, study finds
on April 18, 2018 at 4:24 pm
Gene replacement therapy once sounded like science fiction, but today it's making its way to mainstream medicine. Researchers at Lurie Children's Hospital began a study looking at the therapy’s promise four years ago, and it has already yielded some ... […]
Gene Therapy May Be Cure for Some With Rare Blood Disorder
on April 18, 2018 at 3:28 pm
WEDNESDAY, April 18, 2018 (HealthDay News) -- Wanda Sihanath didn't like the fact that her inherited blood disorder would not allow her to travel far from Chicago to attend college, but what could she do? Without regular transfusions and blood testing, the ... […]
Gene therapy helps patients avoid blood transfusion
on April 18, 2018 at 2:31 pm
(CNN)Memories of classical ballet performances dance in Wanda Sihanath's head when she thinks about her childhood in Elgin, Illinois. She remembers balancing at the barre to Beethoven and pirouetting to Vivaldi. Even though it rarely affected her dance ... […]
Gene therapy could free some people from a lifetime of blood transfusions
on April 18, 2018 at 2:19 pm
A one-time, experimental treatment for an inherited blood disorder has shown dramatic results in a small study. It’s a major milestone for the company that created it, Bluebird Bio, and the latest in a string of successes for gene therapies, which aim to ... […]
Gene therapy for blood disorder ends need for transfusions
on April 18, 2018 at 2:08 pm
Gene therapy for transfusion-dependent thalassemia, an inherited blood disorder, produced positive outcomes in an interim analysis of two international Phase 1/2 clinical trials, according to the results published in New England Journal of Medicine. […]
Gene Therapy For Inherited Blood Disorder Reduced Transfusions
on April 18, 2018 at 2:01 pm
Gene therapy is showing promise for treating one of the most common genetic disorders. Results of a study published Wednesday show that 15 of 22 patients with beta-thalassemia who got gene therapy were able to stop or sharply reduce the regular blood ... […]
Gene–Drug Interaction Map Developed to Aid Personalized Chemotherapy
on April 18, 2018 at 7:05 am
"We know very little about how gene mutations in tumor cells can change how a tumor ... and ovarian cancer resistance to PARP inhibitor therapy. Through a collaboration with Clovis Oncology, they were the able to confirm that ovarian cancer patients ... […]
BRIEF-AGTC Doses First Patient In Phase 1/2 Clinical Study Of Gene Therapy For Treatment Of X-Linked Retinitis Pigmentosa
on April 18, 2018 at 4:24 am
April 18 (Reuters) - Applied Genetic Technologies Corp : * AGTC DOSES FIRST PATIENT IN PHASE 1/2 CLINICAL STUDY OF GENE THERAPY FOR TREATMENT OF X-LINKED RETINITIS PIGMENTOSA Source text for Eikon: Further company coverage: Our Standards:The Thomson ... […]
via Google News and Bing News